All presentations of terazosin are being discontinued.
On this page
- About this discontinuation
- What people taking terazosin need to know
- Key dates for prescribers and pharmacists
- What prescribers need to know
- What pharmacists need to know
- Who to contact
Apotex, the supplier of terazosin (Apo-Terazosin) 2 mg and 5 mg tablets, notified PHARMAC that current stock of Apo-Terazosin in New Zealand would be exhausted by September for the 2 mg strength and mid-November for the 5 mg strength.
Link Pharmaceuticals have sourced a limited supply of an unapproved brand of terazosin, Teva Terazosin. This will be available in New Zealand early October 2020. Teva Terazosin will assist in the transition to alternative products.
PHARMAC has been unsuccessful in sourcing a long-term supply of terazosin 2 mg and 5 mg tablets. Prescribers will need to transition patients to an alternative funded agent.
PHARMAC can no longer source Apo-terazosin. If you are taking Apo-Terazosin, you will need to talk to your prescriber about alternative medicines.
To help with your transition to a new medicine, we have sourced a short term supply of another brand of terazosin, Teva Terazosin. This brand is not an approved medicine in New Zealand. If you and your prescriber decide that Teva Terazosin is the best option for you, there are extra requirements your doctor must meet when prescribing it for you.
- September 2020 – Current stock Apo-Terazosin 2 mg expected to run out
- 1 October 2020 – No new patients’ endorsement for terazosin in the Pharmaceutical Schedule
- 1 October 2020 – Teva Terazosin (unapproved Schedule 29) listed in the Pharmaceutical Schedule
- Early October 2020 – Teva Terazosin (unapproved Schedule 29) 2mg, 5 mg stock available in New Zealand
- Mid November 2020 – Current stock Apo-Terazosin 5 mg expected to run out
- May 2021 – Stock of Teva Terazosin is expected to run out
- Mid 2021 – Apo-Terazosin and Teva terazosin delisted from the Pharmaceutical Schedule.
Prescribers will need to:
- Ensure no new patients are started on terazosin from 1 October 2020.
- Support your patients who are currently using terazosin to change to an alternative treatment by May 2021.
We have not been able to secure long-term supply of a registered terazosin. Link Pharmaceuticals have sourced a limited supply of an unapproved brand of terasozin, Teva Terazosin. This will be available in New Zealand early October 2020 to assist in transitioning patients to alternative products.
Teva Terazosin is an unapproved medicine in New Zealand. As such, it needs to be supplied in line with section 29 of the Medicines Act 1981. Prescribers need to be familiar with their obligations under section 29.
Only medical practitioners registered with the Medical Council of New Zealand can prescribe section 29 medicines. We appreciate that this limits the ability of non-medical prescribers to prescribe this medicine. We apologise for any inconvenience this causes.
What you need to know about Teva Terazosin:
- Teva Terazosin tablets have the same active ingredient, at the same strength, as Apo-Terazosin tablets
- Teva Terazosin has been approved for use in the UK
- Teva Terazosin tablets (2 mg and 5 mg) will be:
- Listed in the Pharmaceutical Schedule from 1 October 2020
- Available for distribution early October 2020
- Delisted from the Pharmaceutical Schedule mid 2021 once the stock is exhausted.
What section 29 means
Section 29 allows for medicines that are not Medsafe approved to be supplied to patients. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – that is medical practitioners ie medical doctors.
To ensure continuity of supply and allow people to transition to alternative products, we will list Teva Terazosin, 2 mg and 5 mg tablets on the Pharmaceutical Schedule from 1 October 2020. Link Pharmaceuticals is supplying the Teva product.
|Chemical and presentation||Brand||Pharmacode||Pack size||Subsidy and price
(ex-man., ex. GST)
|Terazosin tab 2 mg||Teva||2599880||28||$14.20|
|Terazosin tab 5 mg||Teva||2599899||28||$24.80|
Teva Terazosin is an unapproved medicine and will need to be supplied in accordance with Section 29 of the Medicines Act. Wastage rules will apply.
As PHARMAC has been unsuccessful in sourcing an alternative long-term supply of terazosin 2 mg and 5 mg tablets. People using terazosin should be advised to visit their prescriber to change to an alternative treatment.
Mid-2021 – Apo-Terazosin and Teva Terazosin will be delisted from the Pharmaceutical Schedule
If you are a prescriber or pharmacist with questions about this supply issue, email firstname.lastname@example.org
If you have a question for the distributor, contact Link Pharmaceuticals (external link)
If you take terazosin, your doctor, nurse or pharmacist are the best people to answer your questions. PHARMAC cannot give clinical advice to anyone.
Terazosin update: 11 September 2020
Apotex has advised that their brand of terozosin (Apo-Terozosin) 2 mg and 5 mg tablets are in short supply.
- 2 mg tablets – stock will run out by mid-September 2020
- 5 mg tablets – stock will run out by mid-November 2020
Some pharmacies may still have stock to fill prescriptions, but this will be limited and unevenly distributed across the country. We are working to secure additional stock of terazosin 2 mg and 5 mg tablets.
We have received clinical advice about the alternative funded alpha-adrenoceptor blockers listed on the Pharmaceutical Schedule.
Terazosin (Apo-Terazosin) is an alpha adrenoceptor blocker used to treat symptoms of an enlarged prostate (benign prostatic hyperplasia) and high blood pressure. Approximately 20,900 people take funded terazosin in New Zealand.
Information for people taking terazosin
If you are taking Apo-terazosin talk to your doctor or specialist about alternative options. Your doctor will advise whether any of the alternatives we have listed on the Pharmaceutical Schedule are suitable for you.
Information for prescribers
If you have a patient who takes terazosin carefully and actively consider changing them to another treatment as we cannot guarantee that we will be able to secure additional stock. From 1 October 2020 you should not start any new patients on terazosin.
We have received clinical advice, including from our cardiovascular subcommittee. The clinical advice is:
- there are alternative and suitable funded alpha adrenoceptor blockers listed on the Pharmaceutical Schedule, such as doxazosin.
- there are specialised clinical conditions (other than hypertension and benign prostatic hyperplasia) where terazosin is used. There are funded alternatives for these indications.
We appreciate that it is difficult to change patients onto different medicines and apologise for the any inconvenience this causes.
Information for pharmacists
Advise people taking Apo-terazosin to visit their prescriber to change to an alternative medicine.
We have advised prescribers that patient who take terazosin they will need to change to another treatment. From 1 October 2020 prescribers should not start any new patients on terazosin.
Who to contact
If you take terazosin talk to your doctor or specialist. PHARMAC cannot give you clinical advice.
If you have questions about funding you can:
- email email@example.com
- phone 0800 660 050
Last updated: 29 September 2020